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Abstract 
Breast cancer is considered as a heterogeneous disease comprising various types of neo-
plasms, which involves different profile changes in both mRNA and micro-RNA (miRNA) 
expression. Extensive studies on mRNA expression in breast tumor have yielded some very 
interesting findings, some of which have been validated and used in clinic. Recent miRNA 
research advances showed great potential for the development of novel biomarkers and 
therapeutic targets. miRNAs are a new class of small non-coding regulatory RNAs that are 
involved in regulating gene expression at the posttranscriptional level. It has been demon-
strated that miRNA expression is frequently deregulated in breast cancer, which warrants 
further in-depth investigation to decipher their precise regulatory role in tumorigenesis. We 
address briefly the regulatory mechanism of miRNA, the expression of miRNAs in tumor-
igenesis, and their potential use as breast cancer biomarkers for early disease diagnosis and 
prognosis. In addition, we discuss the use of the Formalin-Fixed, Paraffin-Embedded (FFPE) 
tissue as an invaluable source for breast cancer biomarker discovery and validation, and the 
potential use of circulating miRNAs in blood for early breast cancer detection. We envision 
the potential use of miRNAs in breast cancer management in the near future, particularly in 
improving the early diagnosis, prognosis and treatment. 
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Regulatory mechanisms of miRNAs 
MicroRNAs (miRNAs) are a new class of small 
non-coding  regulatory  RNAs  that  are  involved  in 
regulating gene expression at the posttranscriptional 
level. These small (18–24 nucleotides in length) RNA 
molecules  regulate  numerous  biological  processes. 
The base-pairing  interactions between miRNAs and 
their target mRNAs, often within the 3’ untranslated 
regions (UTR) of target genes, results in degradation 
and/or translation inhibition of the target genes  [1] 
[2].  Although  the  complementary  binding  to  the  3’ 
UTR  is  not  necessarily  perfect,  it  results  in  transla-
tional  repression.  In  contrast,  the  complementary 
binding within the open reading frame (ORF) needs 
almost perfect match in order for Ago2 to cleave or 
degrade  target  mRNAs  [3]  [4].  miRNAs,  generally 
transcribed by RNA polymerase II, are initially made 
as  large  RNA  precursors,  called  pri-miRNAs  [5]. 
Transcription of miRNA genes are regulated through 
the modulation of various transcription factors as that 
of protein-coding genes [6]. About 1000 miRNA genes 
are thought to be encoded in the human genome [7] 
[8]. A total of 1048 human miRNAs have been identi-Journal of Cancer 2011, 2 
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fied  according  to  miRBase  Release  16  (September 
2010) 
(http://www.mirbase.org/cgi-bin/mirna_summary.
pl?org=hsa) [9] [10]. miRNAs and their targets seem 
to form a complex regulatory network. It is believed 
that a single miRNA can regulate multiple mRNAs 
and a single mRNA can be targeted by a number of 
different  miRNAs.  There  are  about  one  third  of  all 
human  protein-coding  genes  that  are  regulated  by 
miRNA based on computational predictions [11].  
miRNA expression in human cancer.  
The role of miRNAs in cancer was initially sus-
pected  based  on  the  observation  that  miRNA  con-
trolled aspects of cell proliferation and apoptosis in C. 
elegans and  Drosophila [12]  [13].  miRNA  genes  were 
located at fragile sites in the genome, which are fre-
quently amplified or deleted in human cancers  [14] 
and  other  genetic  diseases,  such  as  fragile  X  syn-
drome. Generally, genes encoding miRNAs located in 
chromosomal  regions  that  are  amplified  in  cancers 
function as oncogenes while those deleted in cancers 
may act as tumor suppressors. Expression of various 
miRNAs has been reported to be differentially altered 
across a variety of tumor types, suggesting their direct 
involvement in oncogenesis [3] [15] [16]. Deregulated 
miRNA expression profiles were identified in many 
human  cancers  using  different  miRNA  profiling 
techniques. miRNAs have been associated with em-
bryogenesis and stem cell maintenance [17], hemato-
poietic stem cell differentiation [18], and cancers [19] 
[20] [21]. Many studies show that miRNA expression 
appeared to be deregulated in cancer versus normal 
tissue  [22]  [14,  23]  [24].  Since  those  initial  studies, 
examples of miRNA deregulation have been shown in 
chronic lymphocytic leukemia [25], B-cell lymphoma 
[26]  [27]  and  breast  cancer  [19]  [28]  [29]  [30,  31]. 
However,  it  is  not  clear  whether  the  changes  in 
miRNA expression are a cause or effect of the disease 
for many miRNA species.  
Role of miRNA in breast cancer  
Although  extensive  research  on  molecular 
mechanisms involved in breast cancer has been done 
over the decades, challenges still prevail in the early 
diagnosis and management of breast cancer patients, 
such as unpredictable response and development of 
resistance to adjuvant therapies. miRNAs, as mRNA 
regulators,  could  serve  as  novel  diagnostic  and 
prognostic candidates, and potential therapeutic tar-
gets. Since the miRNA deregulation in breast cancer 
was first reported in 2005 [28], there have been many 
studies  on  the  expression  of  various  miRNAs  and 
their roles in breast cancer as summarized (Table 1).  
Table 1 miRNAs function as tumor suppressors or oncogenes in breast cancer. 
miRNAs  Targets  Functional pathways  References 
Tumor suppressor miRNAs 
miR-206  ESR1  ER signaling  [28, 32] 
miR-17-5p  AlB1,CCND1,E2F1  Proliferation  [33, 34] 
miR-125a,b  HER2,HER3  Anchorage-dependent growth  [35, 36] 
miR-200c  BMl1,ZEB1,ZEB2  TGF-beta signaling  [37-39] 
let-7  H-RAS, HMGA2, LIN28,PEBP1  Proliferation,differetiation  [40-42] 
miR-34a  CCND1,CDK6,E2F3,MYC  DNA damage, proliferation  [43-45] 
miR-31  FZD3,ITGA5,M-RIP,MMP16,RDX,RHOA  Metastasis  [46] 
miR-335  SOX4,PTPRN2,MERTK,TNC  Metastasis  [47] 
miR-27b  CYP1B1  Modulation of the response of tumor to anti-cancer drugs  [48, 49] 
miR-126  IRS-1  Cell cycle progression from G1/G0 to S  [50] 
miR-101  EZH2  oncogenic and metastatic activity  [51] 
miR-145  miR-145 in p53-mediated repression of 
c-Myc. 
Suppresses Cell Invasion and Metastasis  [52] 
miR-146a/b  NF-κB  negatively regulate factor-κB, and impaired invasion and mi-
gration capacity 
[53] 
miR-205  ErbB3 and VEGF-A expression  inhibits tumor cell growth and cell invasion,  [54] 
Oncogenic miRNAs 
miR-21  BCL-2,TPM1,PDCD4,PTEN,MASPIN  Apoptosis  [55-58] 
miR-155  RHOA  TGF-beta signaling  [59] 
miR-10b  HOXD10  Metastasis  [60] 
miR-373/520c  CD44  Metastasis  [61] 
miR-27a  Zinc finger ZBTB10, Myt-1  Cell cycle progression G2- M checkpoint regulation  [62] 
miR221/222  p27Kip1  Tamoxifen resistance  [63] 
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miRNA profiling studies have led to the identi-
fication of miRNAs that are aberrantly expressed in 
human  breast  cancer,  with  miR-10b,  miR-125b  and 
miR-145  being  down-regulated  and  miR-21,  and 
miR-155 being up-regulated. More recent studies have 
not only identified miRNA downstream targets but 
also  associated  particular  miRNA  expression  with 
prognostic  information.  The  miRNAs  have  either 
been  shown  to  be  consistently  up-regulated  or 
down-regulated.  Tumor  formation  may  arise  from 
down-regulation of a tumor suppressor miRNA and / 
or overexpression of an oncogenic miRNA. miRNA 
expression studies in breast cancer also revealed the 
importance and potential use in tumor classification 
and better prognosis. [28] Twenty-nine differentially 
expressed miRNAs were identified when comparing 
breast cancer tissue with normal, and a subset of 15 
miRNAs could be used to discriminate tumor from 
normal.  In  addition,  miRNA  expression  correlated 
with clinical-pathological features such as ER and PR 
expression  (miR-30)  and  tumor  stage  (miR-213  and 
miR-203). The differential expression of several  let-7 
isoforms was associated with clinical-pathologic fea-
tures including PR status (let-7c), lymph node metas-
tasis (let-7f-1, let-7a-3, let-7a- 2), or high proliferation 
index (let-7c, let-7d) in tumor samples. Interestingly, 
unique sets of miRNAs were identified to be associ-
ated  with  breast  cancers  currently  defined  by  their 
HER2/neu or ER/PR status [35]. Significantly, there 
was overlap between the miRNAs identified in both 
studies.  
In recent years, the functional role of miRNAs in 
tumor initiation and progression has been the focal 
point  since  the  discovery  of  the  role  of  miR-10b  in 
breast cancer invasion and metastasis [60]. The study 
indicates that miR-10b is up-regulated in promoting 
invasion and metastasis, whereas down-regulated in 
most  breast  cancer  in  comparison  with  the  normal 
control [28]. Interestingly, miR-10b might not have an 
effect on proliferation due to the fact that almost 50% 
overexpression in metastatic breast cancers compared 
with the low-expression in most breast cancer. Rather 
it  is  mainly  involved  in  breast  cancer  invasion  and 
metastasis, which is validated by migration and inva-
sion assay [60]. These demonstrate that miR-10b may 
confer specific invasive properties only in metastatic 
cells since it is ubiquitously down-regulated in pri-
mary  breast  cancer  cell.  It  has  been  reported  that 
MDA-MB-231  cells  transfected  with  lentivi-
rus-miR-106b have a higher potential of invasion and 
migration, suggesting that miR-106b may play a role 
in  breast  cancer  metastasis  [64].  In  addition,  miR-9, 
upregulated  in  breast  cancer  cells,  directly  targets 
CDH1,  the  E-cadherin-encoding  mRNA,  leading  to 
increased  cell  motility  and  invasiveness  [65].  Inter-
estingly,  miR-378(∗)  was  identified  as  a  molecular 
switch in cancer cell bioenergetics pathway, known as 
the Warburg effect, by regulating ERBB2 expression 
[66]. On the other hand, enhancing the expression of 
some  tumor  suppressor  miRNAs  can  prevent  pro-
gression of breast tumors [67]. For example, the ex-
pression  of  tumor  suppressor  miR-127  can 
down-regulate  the  expression  of  proto-oncogene 
BCL6, a potential target of miR-127 [68].  
Molecular Signatures in Breast Cancer  
Recent advances in phenotyping and expression 
profiling of human cancers have greatly enhanced the 
diagnosis  and  biological  classification  of  several  tu-
mors, in particular breast cancers. Prior to this a very 
limited number of prognostic markers were available 
in clinic beyond those of  histopathological analysis. 
The  microarray-based  gene  expression  signatures 
were identified to classify breast cancers into distinct 
subtypes  largely  based  on  their  ER,  progesterone 
(PR), and HER2 receptor status [69] [70] [71]. Subtypes 
were designated Luminal A, which strongly expressed 
ER and/or PR, but not HER2; Luminal B, which were 
ER, PR and HER2 positive; Basal tumors which were 
ER,  PR,  and  HER  negative,  preferentially  affecting 
young women and women of African origin, usually 
of high histological grade and more aggressive clinical 
behavior [72] . Survival analyses showed significantly 
different outcome for patients based on their tumor 
subtype, suggesting the clinical relevance of molecu-
lar  profiling.  This  method  of  disease  classification 
based on the molecular profiling heralds the promise 
of  personalized  medicine  [73].  Great  scientific  en-
deavors in the field of microarray-based gene expres-
sion  profiling  help  translate  such  technological  ad-
vances to clinical practice in developing new tools for 
accurate  molecular  diagnosis  of  breast  cancer  [74]. 
One such application has been the development of a 
multi-gene assay to predict the recurrence of tamoxi-
fen-treated,  node-negative  breast  cancer  (Oncotype 
DX) [75]. This and other similarly novel genomic tests, 
such  as  MammaPrint,  Theros  and  MapQuant  Dx, 
prove the feasibility of accelerating the transition from 
traditional to molecular medicine. With more studies, 
miRNA signatures, which are currently showing ca-
pability of accurately classifying tumors according to 
currently available prognostic variables, would serve 
as novel biomarkers for diagnosis and treatment. An 
interrogation of miRNA expression profiling in breast 
cancer  classification  could  further  characterize  the 
molecular  basis  and  define  more  precise  subsets  of 
breast  cancer  for  the  identification  of  novel  targets 
that can be exploited for targeted therapy. Journal of Cancer 2011, 2 
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miRNA  expression  levels  should  represent  the 
functional activity of the gene more accurately com-
pared  with  the  those  of  mRNAs,  which  have  to  be 
translated to proteins to attain their biological effects 
[76]. Thus, miRNAs can be novel targets to further our 
understanding in breast cancer diagnosis at the mo-
lecular level. At the same time, miRNAs can be used 
as cancer therapeutic agents when breast cancers can 
be classified based on their miRNA signatures. Fur-
thermore, in each particular cancer or disease devel-
opmental  stage,  specific  miRNAs  with  their  impli-
cated signaling pathways  need to be elucidated. Of 
interest,  the  identity  and  functions  of  each  cell  are 
reflected  by  a  unique  miRNA  expression  signature 
[22,  77].  Since  a  single  miRNA  can  target  multiple 
genes of a particular signaling pathway, it is therefore 
more feasible to target miRNAs involved in a partic-
ular cellular process, rather than targeting one mRNA 
[22].  For  example,  introduction  of  anti-miR-21  to 
MCF-7  breast  cancer  cells  and  a  xenograft  mouse 
model  considerably  suppressed  miR-21  expression, 
which resulted in decreased cell growth via increased 
apoptosis and reduced cell proliferation  [78]. Topo-
tecan can increase the tumor growth reduction capac-
ity of anti-miR-21, indicating that suppression of the 
oncogenic miR-21 can sensitize cancer cells to chem-
otherapy, which is helpful for patients who show re-
sistance to chemotherapeutic agents [78]. Recent re-
port  showed  that  miR-125b  expression  causes  a 
marked  inhibition  of  paclitaxel-induced  cytotoxicity 
and apoptosis by targeting is the pro-apoptotic Bak1, 
which  could  help  explain  the  paclitaxel-resistant  in 
breast cancer [79]. 
miRNA expression profiling from FFPE tis-
sues. 
FFPE  (Formalin-Fixed,  Paraffin-Embedded)  tis-
sues  are  an  invaluable  resource  for  biomarker  dis-
covery and validation. The formalin fixation process 
allows for permanent preservation of the architecture 
of tissues in optimal histological condition and easy 
long-term  storage.  However,  this  process  compro-
mises  the  yield,  quality  and  integrity  of  mRNA 
through degradation, cross-linking with proteins and 
various  chemical  modifications  [80]  [81].  miRNAs, 
due to their small size, are potentially more robust to 
degradation than mRNAs during the process. There-
fore miRNA expression profiling could be more reli-
able using FFPE tissues. Recent report indicated that 
correlations of expression profiles between fixed and 
frozen mouse liver tissues are higher with miRNAs 
than  with  mRNAs  [82].  miRNAs  can  efficiently  be 
detected  by  qRT-PCR  in  archived  colorectal  cancer 
specimens up to 10 years and in liver specimens up to 
30 years [83], suggesting that miRNAs are better al-
ternative for expression analyses in archived samples, 
such  as  FFPE  samples.  In  addition,  it  has  been 
demonstrated  in  multiple  studies  that  miRNAs  are 
minimally affected by FFPE treatment, and miRNAs 
extracted from FFPE samples provide reliable expres-
sion levels by direct comparison with frozen samples 
[82] [84] [85] [86]. Furthermore, we have recently iso-
lated  miRNAs  from  microdissected  breast  tissues 
successfully  using  the  RecoverAll  Total  Nucleic  Acid 
Isolation Kit from Ambion. The isolated miRNAs were 
used in both miRNA microarray expression profiling 
study  as  well  as  real-time  QPCR  valiadation  (un-
published data). Taken together, these demonstrated 
that the FFPE tissue would be an invaluable source for 
miRNA expression study and marker validation.  
Circulating miRNAs as early diagnostic bi-
omarkers  
miRNAs  in  the  circulation  system  might  func-
tion as feasible biomarkers in early stage breast cancer 
detection. Since miRNAs are exceptionally stable in 
visceral tissue, it is plausible if those serum preserved 
miRNAs are detectable, and quantifiable in the circu-
lation system. Those promising ideas are generating 
great  excitement  in  both  clinic  and  scientific  fields. 
After the serum preserved miRNAs were first docu-
mented within the patients with diffuse large B-cell 
lymphoma  [87],  subsequent  studies  has  continually 
reported the presence of miRNAs in circulation sys-
tem and body fluid, and hypotheses that their poten-
tial for use as novel biomarkers for disease and phys-
iological  states  including  invasive  cancers,  diabetes 
mellitus and even pregnancy [88-91]. This concept still 
needs  further  extensive  investigation  to  validate, 
however,  due  to  the  limited  methodologies,  small 
numbers  and  great  deficiency  interrogations  have 
been made in this area, especially in breast cancer. If 
the  detection  of  invasive  metastasizing  cancer  cells 
and  their  miRNAs  migration  to  the  lymph  node  is 
feasible,  their  potential  use  as  minimally  invasive 
biomarker  would  be  an  incredible  breakthrough  in 
disease monitoring, and in particularly, serves as sig-
nificant  control  to  study  the  comparatively  poorly 
invasive early stage cancer cells.  
Limitations of current methodologies of dis-
covering molecular biomarkers for breast 
cancer  
Microdissection of the archived FFPE tumor tis-
sue provides great potential, as one can compare the 
expression  profiling  of  the  different  regions  of  the 
tumor representing specific histological types within Journal of Cancer 2011, 2 
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the same genetic background. Nevertheless, based on 
the  current  multistep  carcinogenesis  model,  which 
predicts tumor cells might consecutively acquire al-
ternations in genomics and epigenomics before they 
escalate toward more aggressive phenotype. It’s very 
likely that those small metastasizing cells, which may 
have acquired additional mutations that are not pre-
sent in the primary tumor [92-96], could escape the 
detection by current expression profiling techniques, 
unless the tumor cells can be sub-grouped and ana-
lyzed separately, which is not an easy task. The fate of 
the tumor is determined from the initialization events 
and the following genomic and / or epigenomic mu-
tations. It might also depend on the origin of the cells 
[97].  Microarray  profiling  is  suitable  to  detect  both 
cellular origins and subsequent mutations. However 
this  does  not  exclude  the  possibility  that  the  meta-
static phenotype is inherited by an accident mutation 
from a single metastatic cell in the primary tumor or a 
non-invasive cell acquires the de nova invasive po-
tential characteristic. On the other hand, even though 
microarray technology is relatively mature, numbers 
of  expression  alterations  could  still  be  attributed  to 
differences  in  the  technology  rather  than  biology, 
which is why it requires careful and rigorous valida-
tions using a large number of samples.  
Apparently, the miRNA microarray has the po-
tential  to  alleviate  the  dilemma  and  provides  more 
robust data as miRNAs are so small in size and pro-
portionally have less possibility of alternative splicing 
and less vulnerability to intrinsic platforms. However, 
since the miRNA expression is tissue specific, and the 
degradation  of  mRNA  endogenous  control  in  long 
time  FFFPE  archived  tissue  is  commonly  severe, 
which would certainly challenge the availability and 
reliability  of  the  endogenous  controls  [98]  [99].  In-
stead, we have to identify more new reliable endog-
enous miRNA markers to serve as controls. In addi-
tion, sample collection is of concern because most of 
the  breast  cancer  patients  have  received  adjuvant 
chemotherapy. It is hard to determine whether a tu-
mor without metastasis is due to chemotherapy.  
Conclusions 
The  biological  function  of  miRNAs  in  breast 
cancer is diverse, comprehensive and remains to be 
fully understood. The involvement of miRNAs in the 
initiation and progression of breast cancer holds great 
potential for new development in current diagnostic 
and  therapeutic  strategies  in  breast  cancer  manage-
ment. Each year more than 1.3 million women will be 
diagnosed  with  breast  cancer  globally  and  about 
465,000 will die from the disease despite the fact that 
breast cancer is still highly curable if only diagnosed 
and treated appropriately at the early stage. At the 
cellular  level,  not  all  early  stage  tumor  cells  will 
eventually progress into notorious invasive carcino-
ma, otherwise need aggressive chemotherapy which 
will generate intense physical and financial trauma to 
the patient. So it is invaluable to establish a reliable 
and confident detecting and scoring system to guide 
the clinic to avoid over-treatment to the patients who 
do not benefit from aggressive standard treatment.  
miRNAs would provide easily accessible, sensi-
tive, reliable data resources to shed light on the re-
search of early stage breast cancer development and 
progression. Combined with other existing technolo-
gies, miRNA microarrays and / or miRNA deep se-
quencing  would  identify  novel  miRNA  biomarkers 
that could be used for more accurate early detection, 
prognosis  and  targeted  therapy.  Of  note,  scientific 
endeavors on the functional investigation of miRNAs 
and their targets will elucidate the intrinsic molecular 
mechanisms of breast cancer development and pro-
gression. 
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